explore -WSS

explore

author：fashion 2025-09-29 20:51:14 - browse：3

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Bird flu in milk supply is likely coming from asymptomatic cows

WSS

Appeals court upholds limits to abortion pill

AstraZeneca challenges Medicare drug negotiation program

Getting Alzheimer's drug Leqembi to patients can be a challenge

Bird flu in milk supply is likely coming from asymptomatic cows

UnitedHealth financials solid despite Change Healthcare cyberattack

Close Medicare's dangerous gaps in addiction treatment coverage

leisure time

explore

explore

Trump demands the U.S. pay no more for drugs than other countries … again

Bird flu in milk supply is likely coming from asymptomatic cows

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cue Health's Covid

Dobbs anniversary: the lost opportunity of abortion as health care

Psilocybin's anti

New air purifier tech could be key to improving indoor air quality

Departing Stanford president retracts two papers

Anesthesiologist group: stop taking Ozempic before surgery

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

explore

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

After traumatic brain injury, life support decisions can use more time

FTC falls short on scrutinizing hospital mergers, study says

Medicare explains how it will choose drugs for negotiation

Cancer researcher Catriona Jamieson is sending tumors into space

Getting Alzheimer's drug Leqembi to patients can be a challenge

hotspot

focus

hotspot

Wikipedia